Display options
Cite
Chavira A, Belda-Ferre P, Kosciolek T, et al. The Microbiome and Its Potential for Pharmacology. Handb Exp Pharmacol. 2019;260:301-326doi: 10.1007/164_2019_317.
Chavira, A., Belda-Ferre, P., Kosciolek, T., Ali, F., Dorrestein, P. C., & Knight, R. (2019). The Microbiome and Its Potential for Pharmacology. Handbook of experimental pharmacology, 260301-326. https://doi.org/10.1007/164_2019_317
Chavira, Aries, et al. "The Microbiome and Its Potential for Pharmacology." Handbook of experimental pharmacology vol. 260 (2019): 301-326. doi: https://doi.org/10.1007/164_2019_317
Chavira A, Belda-Ferre P, Kosciolek T, Ali F, Dorrestein PC, Knight R. The Microbiome and Its Potential for Pharmacology. Handb Exp Pharmacol. 2019;260:301-326. doi: 10.1007/164_2019_317. PMID: 31820171.
Copy Download .nbib Format: NLM
Share it on

Handb Exp Pharmacol. 2019;260:301-326. doi: 10.1007/164_2019_317.

The Microbiome and Its Potential for Pharmacology.

Handbook of experimental pharmacology

Aries Chavira, Pedro Belda-Ferre, Tomasz Kosciolek, Farhana Ali, Pieter C Dorrestein, Rob Knight

Affiliations

  1. Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA.
  2. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
  3. Ma?opolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
  4. Division of Gastroenterology, Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
  5. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
  6. Collaborative Mass Spectrometry Innovation Center, University of California San Diego, La Jolla, CA, USA.
  7. Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.
  8. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. [email protected].
  9. Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA. [email protected].
  10. Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA. [email protected].
  11. Department of Bioengineering, University of California San Diego, La Jolla, CA, USA. [email protected].

PMID: 31820171 DOI: 10.1007/164_2019_317

Abstract

The human microbiota (the microscopic organisms that inhabit us) and microbiome (their genes) hold considerable potential for improving pharmacological practice. Recent advances in multi-"omics" techniques have dramatically improved our understanding of the constituents of the microbiome and their functions. The implications of this research for human health, including microbiome links to obesity, drug metabolism, neurological diseases, cancer, and many other health conditions, have sparked considerable interest in exploiting the microbiome for targeted therapeutics. Links between microbial pathways and disease states further highlight a rich potential for companion diagnostics and precision medicine approaches. For example, the success of fecal microbiota transplantation to treat Clostridium difficile infection has already started to redefine standard of care with a microbiome-directed therapy. In this review we briefly discuss the nature of human microbial ecosystems and with pathologies and biological processes linked to the microbiome. We then review emerging computational metagenomic, metabolomic, and wet lab techniques researchers are using today to learn about the roles host-microbial interactions have with respect to pharmacological purposes and vice versa. Finally, we describe how drugs affect the microbiome, how the microbiome can impact drug response in different people, and the potential of the microbiome itself as a source of new therapeutics.

Keywords: Drug discovery; Immunology; Immunotherapy; Live biotherapeutics; Metabolism; Microbiology; Microbiome; Microbiota; Patient stratification; Precision medicine

Substances

MeSH terms

Publication Types